The Anti-Inflammatory and Cytoprotective Efficiency of Curvularin, a Fungal Macrolactone against Lipopolysaccharide-Induced Inflammatory Response in Nucleus Pulposus Cells: An Study
| Autor: | Subbaiah Gpv, Gurava Reddy Av, Rajkiran Reddy Banala, Sherline Ev, Satish Kumar Vemuri |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Lipopolysaccharide
medicine.drug_class Inflammation Pharmacology macrolactone Anti-inflammatory 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine Orthopedics and Sports Medicine Viability assay Dexamethasone 030304 developmental biology 0303 health sciences nonsteroidal anti-inflammatory drugs intervertebral disc degeneration business.industry lipopolysaccharide Interleukin Curvularin Basic Study cytokines chemistry inflammation Medicine Surgery Tumor necrosis factor alpha curvularin medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Asian Spine Journal, Vol 15, Iss 2, Pp 143-154 (2021) Asian Spine Journal |
| ISSN: | 1976-7846 1976-1902 |
| Popis: | Study Design: Developing an in vitro model for assessing the anti-inflammatory properties of curvularin.Purpose: To evaluate the efficacy of natural fungal macrolactone as a therapeutic drug against lipopolysaccharide (LPS)-induced inflammation in primary human nucleus pulposus cells (NPCs) in vitro.Overview of Literature: Lumbar disk disease is a common cause of lower back pain (LBP) and sciatica. It is an established fact that inflammation, rather than mechanical compression on the nerve root, plays a role in the cause of LBP and sciatica. Current treatment options for reducing inflammation are either nonsteroidal anti-inflammatory drugs or steroids, prolonged use of which can potentially lead to adverse effects such as gastrointestinal disturbances and renal and cardiac issues. Hence, there is a need for better antiinflammatory drugs with no or minimal complications for treating inflammation-induced LBP and sciatica. Curvularin (Cur), a fungal macrolactone, is known for its anti-inflammatory activity, but nothing is known about its impact on inflammation due to disk pathologies.Methods: Primary NPCs were cultured and characterized by flow cytometry and immunocytochemistry using the CD24 antibody and treated with 10 μg/mL LPS for 36 hours and then treated with Cur, betamethasone, and dexamethasone (10 μg/mL) for 48 hours, after which cell cycle analysis, cell viability assay, and gene expression studies (quantitative polymerase chain reaction [PCR] and quantitative real-time-PCR) were conducted. The NPCs treated with Cur downregulated the expression of pro-inflammatory cytokines (tumor necrosis factor-α, interleukin [IL]-1β, and IL-6); matrix metalloproteinases (MMPs; MMP-2 and MMP-3), ADAMTS; and apoptotic marker (cytochrome c).Results: In our study, Cur-treated cells showed enhanced expression of collagen 9A1 and insulin-like growth factor receptor 1, indicating the recovery of NPCs from inflammatory assault.Conclusions: Based on observations, the anti-inflammatory properties of Cur render it an excellent drug molecule for treating disk degeneration nonsurgically, by direct injection into spinal disks when treating LBP and sciatica. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|